Vaishampayan U - Search Results

1

Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer.

Hussain M, Smith DC, El-Rayes BF, Du W, Vaishampayan U, Fontana J, Sakr W, Wood D. Hussain M, et al. Among authors: vaishampayan u. Urology. 2003 Apr;61(4):774-80. doi: 10.1016/s0090-4295(02)02519-0. Urology. 2003. PMID: 12670564 Clinical Trial.

2

Taxanes: an overview of the pharmacokinetics and pharmacodynamics.

Vaishampayan U, Parchment RE, Jasti BR, Hussain M. Vaishampayan U, et al. Urology. 1999 Dec;54(6A Suppl):22-9. doi: 10.1016/s0090-4295(99)00451-3. Urology. 1999. PMID: 10606281 Review.

3

Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma.

Vaishampayan U, Glode M, Du W, Kraft A, Hudes G, Wright J, Hussain M. Vaishampayan U, et al. Clin Cancer Res. 2000 Nov;6(11):4205-8. Clin Cancer Res. 2000. PMID: 11106233 Clinical Trial.

4

Adjuvant chemo-/hormonal therapy trials for locally advanced prostate cancer.

Vaishampayan U, Hussain M. Vaishampayan U, et al. Curr Oncol Rep. 2000 Sep;2(5):402-8. doi: 10.1007/s11912-000-0059-z. Curr Oncol Rep. 2000. PMID: 11122871 Review.

5

Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer.

Hussain M, Vaishampayan U, Du W, Redman B, Smith DC. Hussain M, et al. Among authors: vaishampayan u. J Clin Oncol. 2001 May 1;19(9):2527-33. doi: 10.1200/JCO.2001.19.9.2527. J Clin Oncol. 2001. PMID: 11331332

6

Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors.

Jimenez RE, Hussain M, Bianco FJ Jr, Vaishampayan U, Tabazcka P, Sakr WA, Pontes JE, Wood DP Jr, Grignon DJ. Jimenez RE, et al. Among authors: vaishampayan u. Clin Cancer Res. 2001 Aug;7(8):2440-7. Clin Cancer Res. 2001. PMID: 11489824

7

Phase II evaluation of paclitaxel, alpha-interferon, and cis-retinoic acid in advanced renal cell carcinoma.

Vaishampayan U, Flaherty L, Du W, Hussain M. Vaishampayan U, et al. Cancer. 2001 Aug 1;92(3):519-23. doi: 10.1002/1097-0142(20010801)92:3<519::aid-cncr1350>3.0.co;2-#. Cancer. 2001. PMID: 11505395 Clinical Trial.

8

Novel gemcitabine-containing triplets in the management of urothelial cancer.

Hussain M, Vaishampayan U, Smith DC. Hussain M, et al. Among authors: vaishampayan u. Semin Oncol. 2002 Feb;29(1 Suppl 3):20-4. doi: 10.1053/sonc.2002.30753. Semin Oncol. 2002. PMID: 11894004 Review.

9

The evolving role of systemic therapy in high risk prostate cancer: strategies for cure in the 21st century.

Vaishampayan U, Hussain M. Vaishampayan U, et al. Crit Rev Oncol Hematol. 2002 May;42(2):179-88. doi: 10.1016/s1040-8428(01)00187-1. Crit Rev Oncol Hematol. 2002. PMID: 12007976 Review.

10

Outcome of relapsed non-Hodgkin's lymphoma patients after allogeneic and autologous transplantation.

Vaishampayan U, Karanes C, Du W, Varterasian M, al-Katib A. Vaishampayan U, et al. Cancer Invest. 2002;20(3):303-10. doi: 10.1081/cnv-120001174. Cancer Invest. 2002. PMID: 12025224

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

307 results

Search Page

Filters